Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2201-2208

  Adedoyin, Adedayo ^a   Bernardo, José F ^a   Swenson, Christine E ^b   Bolsack, Lois E ^b   Horwith, Gary ^b   DeWit, Stephane ^c   Kelly, Edward ^d   Klasterksy, J ^e   Sculier, J P ^e   DeValeriola, D ^e   Anaissie, Elias ^f   Lopez Berestein, Gabriel ^f   Llanos Cuentas, Alejandro ^g   Boyle, Anthony ^b   Branch, Robert A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Liposome Company Incorporated   (United States)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d Clinical Research Unit   (United States)

^e JULES BORDET INSTITUTE   (Belgium)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SOLUBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIPID SOLUBILITY; MAJOR CLINICAL STUDY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0030827228     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2201     Document Type: Article

References (38)

1. Allen, T. M., and C. Hansen. 1991. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068:133-141.
2. Anaissie, E. J., M. White, O. Uzun, C. Singer, G. P. Bodey, D. Matzke, N. Azarnia, and G. Lopez-Berestein. 1995. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis, abstr. LM21, p. 330. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Colette, C., P. Van der Auwerz, P. Lopez, C. Heymans, and F. Meunier. 1989. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob. Agents Chemother. 33:362-368.
4. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:27-38.
5. Gates, C., and R. J. Pinney. 1993. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 18:147-153.
6. Goto, R., and Y. Ibuki. 1994. Tissue distribution of liposomes prepared from synthetic amphiphiles after intraperitoneal injection into mice. Appl. Radiat. Isotopes 45:57-62.
7. Gregoriadis, G. 1991. Overview of liposomes. J. Antimicrob. Chemother. 28:39-48.
8. Harashima, H., Y. Ohnishi, and H. Kiwada. 1992. In vivo evaluation of the effect of the size and opsonization on the hepatic extraction of liposomes in rats: an application of Oldendorf method. Biopharm. Drug Dispos. 13:549-553.
9. Harashima, H., K. Sakata, and H. Kiwada. 1993. Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes. Pharm. Res. 10:606-610.
10. Harashima, H., C. Yamane, Y. Kume, and H. Kiwada. 1993. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J. Pharmacokinetic Biopharm. 21:299-308.
11. Hostetler, J. S., K. V. Clemons, L. H. Hanson, and D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcoses. Antimicrob. Agents Chemother. 36:2656-2660.
12. Huang, S. K., K. D. Lee, K. Hong, D. S. Friend, and D. Papahadjopoulos. 1992. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:5135-5143.
13. Janknegt, R., S. de Marie, I. A. J. M. Bakker-Wondenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokinet. 23:279-291.
14. Joly, V., F. Dromer, J. Barge, P. Yeni, N. Seta, G. Molas, et al. 1989. Incorporation of amphotericin B (AMB) into liposomes alter AMB-induced acute nephrotoxicity in rabbits. J. Pharmacol. Exp. Ther. 251:311-316.
15. Kume, Y., F. Maeda, H. Harashima, and H. Kiwada. 1991. Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system. J. Pharm. Pharmacol. 43:162-166.
16. Litzinger, D. C., and L. Huang. 1992. Amphipathic poly(ethylene glycol) 5000-stabilized dioleolylphosphatidylethanolamine liposomes accumulate in spleen. Biochim. Biophys. Acta 1127:249-254.
17. Litzinger, D. C., A. M. Buiting, N. van Rooijen, and L. Huang. 1994. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1190:99-107.
18. 1 accumulate effectively in spleen. Biochim. Biophys. Acta 1066: 159-165.
19. Liu, D., F. Liu, and Y. K. Song. 1995. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim. Biophys. Acta 1235:140-146.
20. Llanos-Cuentas, A., J. Chang, J. Cieza, J. Echevarría, P. Garcia, and A. Lentnek. 1990. Safety and tolerance of amphotericin B lipid complex vs Fungizone in patients with mucocutaneous leishmaniasis, abstr. 568, p. 181. In Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Lopez-Berestein, G., V. Fainstein, R. Hopfer, K. Mehta, M. P. Sullivan, M. Keating, et al. 1985. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 151:704-710.
22. Lopez-Berestein, G., G. P. Bodey, L. S. Frankel, and K. Mehta. 1987. Treatment of hepatosplenic candidiasis with liposomal-amphotericin Br. J. Clin. Oncol. 5:310-317.
23. Lopez-Berestein, G., G. P. Bodey, V. Fainstein, M. Keating, L. S. Frankel, B. Zeluff. et al. 1989. Treatment of systemic fungal infections with liposomal amphotericin B. Arch. Intern. Med. 149:2533-2536.
24. Medoff, G., F. Valeriote, and J. Dieckman. 1981. Potentiation of anticancer agents by amphotericin B. J. Natl. Cancer Inst. 67:131-135.
25. Meunier, F., J. P. Sculier, A. Coune, C. Brassinne, C. Heyman, C. Laduron. et al. 1988. Amphotericin B encapsulated in liposomes administered to cancer patients. Ann. N. Y. Acad. Sci. 544:598-610.
26. Meunier, F., H. G. Prentice, and O. Ringdén. 1991. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28:83-91.
27. Olsen, S. J., M. R. Swerdel, B. Blue, J. M. Clark, and D. P. Bonner. 1991. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:831-835.
28. Osaka, S., H. Tsuji, and H. Kiwada. 1994. Uptake of liposomes surface-modified with glycyrrhizin by primary cultured rat hepatocytes. Biol. Pharm. Bull. 17:940-943.
29. Poste, G. 1983. Liposome targeting in vivo: problems and opportunities. Biol. Cell 47:19-37.
30. Ralph, E. D., A. M. Khazindar, K. R. Barber, and C. W. Grant. 1991. Comparative in vitro effects of liposomal amphotericin B. amphotericin B-deoxycholate and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother. 35:188-191.
31. Ringdén, O., F. Meunier, J. Tollemar, P. Ricci, S. Tura, and E. Kuse. 1991. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28:73-82.
32. Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Safety 5:94-108.
33. Taylor, R., D. M. Williams, P. C. Craven, J. R. Graybill, D. J. Drutz, and W. E. Magee. 1982. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am. Rev. Respir. Dis. 125:610-611.
34. Torchillin, V. P., M. I. Shtilman, V. S. Trubetskoy, and K. Whiteman. 1994. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim. Biophys. Acta 1195:181-184.
35. Wiebe, V. J., and M. W. DeGregorio. 1988. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev. Infect. Dis. 10:1097-1101.
36. Yamauchi, H., H. Kikuchi, M. Sawada, M. Tomikawa, and S. Hirota. 1994. Characterization and tissue distribution of liposomes containing lactose mono-fatty acid derivatives. J. Microencapsulation 11:179-188.
37. Yamauchi, H., H. Kikuchi, M. Sawada, M. Tomikawa, and S. Hirota. 1994. Selective uptake of liposomes containing lactose mono-fatty acid derivatives by hepatic parenchymal cells. J. Microencapsulation 11:287-296.
38. Yoshioka, S., N. Imaeda, Y. Okano, Y. Mizukami, and Y. Katagiri. 1994. Preferential uptake of lactosylceramide-bearing dipalmitoylphosphatidyl-choline-liposomes into liver: role of membrane fluidity. Biol. Pharm. Bull. 17:640-644.